Clinical Trial

cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer

Study acronym: EpiCORE
Recruiting
View on ClinicalTrials.gov →
Summary
The EpiCORE study aims to identify cfDNA-based epigenetic markers predictive of response to first-line chemotherapy (FOLFOX or FOLFIRI) in metastatic colorectal cancer (mCRC). By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to establish a non-invasive biomarker panel capable of distinguishing responders from non-responders.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-03.
Trial Details
NCT Number NCT07224815
Lead Sponsor City of Hope Medical Center
Conditions CRC (Colorectal Cancer)
Enrollment 600 participants
Start Date 2024-06-21
Primary Completion 2028-06-18 (estimated)
Study Completion 2028-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-07